ARTICLE | Emerging Company Profile
French biotech to pursue novel targets with ADCs incorporating new and old payloads
By Richard Guy, Biopharma Analyst
June 11, 2024 10:47 PM UTC
The management team behind Emergence Therapeutics is teaming up to launch a second ADC company, Adcytherix, less than a year after the acquisition of its first. This time, the focus isn’t on developing a new ADC platform, but on case-by-case optimization of payloads and targets.
Jack Elands, Xavier Preville and Carsten Dehning, Emergence co-founders and CFO, respectively, began working on Adcytherix S.A.S. with Pontifax Venture Capital just months after Emergence was acquired by Eli Lilly and Co. (NYSE:LLY) last year…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652094/adcytherix-emergence-team-reunites-for-another-adc-company